REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy
Yokohama, Japan: August 18 2025 – REPROCELL is proud to announce the introduction of NeoSight - Neoantigen Detection Service, a state-of-the-art, end-to-end platform designed to empower researchers and clinicians with high-confidence neoantigen data for personalized immuno-oncology applications.
This service integrates Next Generation Sequence (NGS) data obtained from whole exome sequencing (WES) of tumor and matched normal samples to pinpoint somatic mutations. This is then paired with transcriptome data to confirm which mutations are actively expressed in the tumor, enhancing the biological relevance of neoantigen candidates.
Sophisticated in-house bioinformatics algorithms then predict tumor-specific peptides with strong affinity for MHC class I and II molecules, guided by the patient’s HLA genotype.
Based on the tumor-specific peptide sequences, the service optionally includes the production of GMP-grade peptide.
This service supports a wide array of cutting-edge applications, including:
- Development of personalized cancer vaccines
- Adoptive immunotherapy
- Response prediction for immune checkpoint inhibitors
- Biomarker discovery for clinical trials
- Tumor immunogenicity profiling in translational research
- Patient stratification based on neoantigen burden and expression.
Dr. Chikafumi Yokoyama, CEO of REPROCELL Inc., commented:
“With over a decade of experience in NGS, cancer diagnostics, immunogenetics, and bioinformatics through the REPROCELL group companies, we are confident to deliver precise and reliable neoantigen insights to accelerate breakthroughs in personalized cancer therapy and discovery.”
Find out more at: https://www.reprocell.com/neoantigen-detection